Epigenomics Overview
- Year Founded
-
1998
- Status
-
Public
- Employees
-
3
- Stock Symbol
-
ECX
- Share Price
-
$0.96
- (As of Monday Closing)
Epigenomics General Information
Description
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.
Contact Information
Website
www.epigenomics.comCorporate Office
- Ziegelhäuser Landstrassee 3
- 69120 Heidelberg
- Germany
Corporate Office
- Ziegelhäuser Landstrassee 3
- 69120 Heidelberg
- Germany
Epigenomics Stock Performance
As of 16-Nov-2026, Epigenomics’s stock price is $0.96. Its current market cap is $857K with 893K shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.96 | $0.97 | $0.96 - $1.80 | $857K | 893K | 216.33 | -$0.31 |
Epigenomics Financials Summary
As of 30-Jun-2026, Epigenomics has a trailing 12-month revenue of $43.2K.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 13,394 | 13,429 | 11,674 | (1,787) |
| Revenue | 43 | 27 | 0 | 367 |
| EBITDA | (323) | (398) | (3,654) | (4,006) |
| Net Income | (278) | (354) | (3,627) | (4,830) |
| Total Assets | 13,246 | 13,643 | 12,333 | 14,199 |
| Total Debt | 12,996 | 13,368 | 11,844 | 13,142 |
Epigenomics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Epigenomics Comparisons
Industry
Financing
Details
Epigenomics Competitors (41)
One of Epigenomics’s 41 competitors is InCellDx, a Venture Capital-Backed company based in Hayward, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| InCellDx | Venture Capital-Backed | Hayward, CA | ||||
| Foundation Medicine | Formerly VC-backed | Boston, MA | ||||
| Asuragen | Formerly VC-backed | Austin, TX | ||||
| Illumina | Formerly VC-backed | San Diego, CA | ||||
| Enzo Biochem | Private Equity-Backed | Farmingdale, NY |
Epigenomics Patents
Epigenomics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024074558-A1 | Improved methods for detecting cancer | Inactive | 04-Oct-2022 | ||
| WO-2024075020-A1 | Multi-analyte diagnostic and prognostic assays for colorectal cancer and uses thereof | Inactive | 04-Oct-2022 | ||
| WO-2023017001-A1 | Improved methods for detecting colorectal cancer | Inactive | 09-Aug-2021 | ||
| EP-4185714-A1 | Methods for detecting liver cancer | Pending | 21-Jul-2020 | ||
| WO-2022018127-A1 | Methods for detecting liver cancer | Inactive | 21-Jul-2020 | C12Q1/6886 |
Epigenomics Signals
Epigenomics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Epigenomics FAQs
-
When was Epigenomics founded?
Epigenomics was founded in 1998.
-
Where is Epigenomics headquartered?
Epigenomics is headquartered in Heidelberg, Germany.
-
What is the size of Epigenomics?
Epigenomics has 3 total employees.
-
What industry is Epigenomics in?
Epigenomics’s primary industry is Diagnostic Equipment.
-
Is Epigenomics a private or public company?
Epigenomics is a Public company.
-
What is Epigenomics’s stock symbol?
The ticker symbol for Epigenomics is ECX.
-
What is the current stock price of Epigenomics?
As of 16-Nov-2026 the stock price of Epigenomics is $0.96.
-
What is the current market cap of Epigenomics?
The current market capitalization of Epigenomics is $857K.
-
What is Epigenomics’s current revenue?
The trailing twelve month revenue for Epigenomics is $43.2K.
-
Who are Epigenomics’s competitors?
InCellDx, Foundation Medicine, Asuragen, Illumina, and Enzo Biochem are some of the 41 competitors of Epigenomics.
-
What is Epigenomics’s annual earnings per share (EPS)?
Epigenomics’s EPS for 12 months was -$0.31.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process